Nano stearic acid and preparation method and application thereof
阅读说明：本技术 一种纳米硬脂酸及其制备方法和用途 (Nano stearic acid and preparation method and application thereof ) 是由 萧湘 于 2020-05-22 设计创作，主要内容包括：本发明公开了一种纳米硬脂酸及其制备方法和用途,所述纳米硬脂酸作为活性成分在用于制备药物、食品、食品添加剂或饲料添加剂中的用途。所述药物用于治疗和/或预防与脂类代谢相关的疾病,所述疾病是肥胖症、阿尔茨海默病或帕金森病。本发明的纳米硬脂酸作为活性成分应用于制备药物、食品、食品添加剂或饲料添加剂,改善了哺乳动物的健康,不仅可以减少肥胖症,还可以提高AD患者的记忆和认知,改善PD患者的健康状态,为肥胖症、阿尔茨海默病(AD)或帕金森病的治疗提供了新方法、新途径和新药物,扩大了纳米硬脂酸的用途。(The invention discloses nano stearic acid and a preparation method and application thereof, and the application of the nano stearic acid as an active ingredient in preparation of medicines, foods, food additives or feed additives. The medicament is used for treating and/or preventing diseases related to lipid metabolism, wherein the diseases are obesity, Alzheimer disease or Parkinson disease. The nano stearic acid is used as an active ingredient to be applied to preparation of medicines, foods, food additives or feed additives, improves the health of mammals, can reduce obesity, can improve the memory and cognition of AD patients, improves the health state of PD patients, provides a new method, a new way and a new medicine for treating obesity, Alzheimer Disease (AD) or Parkinson disease, and expands the application of the nano stearic acid.)
1. The application of nano stearic acid is characterized in that: the application of the nano stearic acid as an active ingredient in the preparation of medicines, foods, food additives or feed additives.
2. The use of nanostearic acid according to claim 1, wherein: the medicament is used for treating and/or preventing diseases related to lipid metabolism, wherein the diseases are obesity, Alzheimer disease or Parkinson disease.
3. The use of nanostearic acid according to claim 1, wherein: the medicament can be granules, capsules, microcapsules, soft capsules, gel, oral liquid, tablets, powder, suppositories, injection, sublingual tablets, ear drops, nose drops or sprays.
4. The use of nanostearic acid according to claim 1, wherein: when the medicine is administered to human in need, the amount of nano stearic acid as active component is not less than 10mg/d, and not less than 1 time/d.
5. The process for preparing nano stearic acid according to any one of claims 1 to 4, wherein: the method comprises the following steps:
1) preparing a surfactant into an aqueous solution;
2) placing the reaction container in a constant-temperature water bath at 65-90 ℃, and adding the aqueous solution prepared in the step 1) into the reaction container;
3) dissolving stearic acid in an organic solvent, and then injecting into the reaction vessel at a constant speed;
4) continuously stirring, adding cooling water when the solution in the reaction container is milky, and then placing the reaction container on ice to continuously stir for 0.5-3.0 h at the rotating speed of 0.7-1.3 k rpm;
5) and after stirring, transferring the reactants in the reaction container to a centrifuge tube, washing with water, and freeze-drying to obtain the nano stearic acid.
6. The method for preparing nano stearic acid according to claim 5, wherein: the surfactant is MYRJ59 or Tween 80, and the organic solvent is at least one of chloroform and a solution of chloroform mixed with acetone or methanol at a volume ratio of 2: 1.
7. The method for preparing nano stearic acid according to claim 6, wherein the stearic acid is plant-derived stearic acid, and the chloroform contains 0.6-0.9% ethanol as a stabilizer.
8. The method for preparing nano stearic acid according to claim 6, wherein: in the step 1), every 100 mg-350 mg of the surfactant is dissolved in 30mL of water.
9. The method for preparing nano stearic acid according to claim 6, wherein: the adding amount of the cooling water in the step 4) is 7-13 mL.
10. A nanometer stearic acid is characterized in that: the nano stearic acid is prepared by the preparation method of the nano stearic acid as claimed in claim 5.
Technical Field
The invention relates to the technical field of preparation and application of nano stearic acid, in particular to nano stearic acid, a preparation method thereof and application thereof in preparing a medicament for treating and/or preventing diseases related to lipid metabolism.
Technical Field
The relation between smoking and Parkinson's Disease (PD) was explored by researchers from the United kingdom a day before, and a paper published in the Neurology journal. Contrary to general belief and advice, researchers have demonstrated the causal protection of the risk of PD from current smoking, which may provide new insights into the etiology of PD.
In the past, there is a paper "relationship between the effect of once smoking and suffering from alzheimer disease-Meta analysis", researchers carried out comprehensive quantitative analysis on 24 documents on the relationship between smoking and AD published outside China, and the conclusion is contrary to the general opinion and suggestion: once smoked the cigarette, the elderly are at reduced risk of AD. (medical information 2011 14 th DOI:10.3969/j. issn.1006-1959.2011.07.400)
A paper published on PLoS One at 29.8.2013 shows that most smokers become obese after quitting smoking. The average weight of the human body can be increased by 4-5 kg within one year, and the main reason is that the food consumption is increased after smoking cessation; on the other hand, scientists have investigated and found that many people have a reduced caloric intake after smoking cessation, but still gain weight. (cooking centre orientations of the generated Changes in the Composition of the intellectual microbiological doi:10.1371/journal. bone. 0059260)
Obesity is inherently related to Alzheimer's disease, and the number of research articles is not sufficient. Smoking is well understood in connection with this.
As shown in Obesity, a paper published in 19 th.5 of this year, it is suggested that obese or overweight people have a smaller hippocampus than normal, and that even those who have suffered Obesity or overweight but have a normal fat mass in the past, have a smaller hippocampus than those who have maintained normal.
The first authors state that "hippocampus, as it ages, is one of the few areas that can continue to form new cells, and usually the first area of the brain affected by alzheimer's disease. "(Antihan Ambikairajah et al, Longitudinal Changes in Fat Mass and the Hippocampus https:// doi.org/10.1002/oby.22819)
However, PD and AD can be said to be two completely different diseases.
PD is the most common disease in dyskinesia, and is often manifested as tremor of the limbs, increased muscle tone, retarded movement, emaciation of unknown origin, and the like; AD is the most common disease in nervous system degenerative diseases, and is mainly manifested as dysfunction of memory and cognition, or even personality change, hallucinations, delusions and other symptoms.
Although the progression of PD to late stages may show some phenomena of amnesic dementia, the progression of AD to late stages may also develop dyskinesias.
However, this is not a reasonable explanation as it is not linked to smoking.
The mechanisms behind PD and AD, which are totally different, are exactly what the mechanisms behind them are why smoking is likely to be protective.
Most of the beliefs are related to the stimulation of dopamine release by nicotine (nicotine), and a clinical trial using a nicotine patch to slow the progression of PD is currently underway (NCT 01560754).
The inventors do not believe this.
It is known that the smoke of a cigarette is a complex mixture of compounds.
The main chemical components of the smoke particulate matter are as follows: aliphatic hydrocarbons, aromatic hydrocarbons, terpenoids, phenolic compounds and organic acids.
The nonvolatile Saturated Fatty Acid (SFA) in the smoke mainly comprises stearic acid (SA, boiling point 183-184 ℃) and palmitic acid (PA, boiling point 351-271.5 ℃).
The temperature of the lit cigarette varies greatly between smoked and unchecked and in different locations. The central temperature of the cigarette end reaches 700-800 ℃, the surface temperature of the cigarette end is about 250 ℃, and the spark temperature of the cigarette end is about 200 ℃.
Stearic Acid (SA), i.e. octadecanoic acid. The chemical formula is as follows: C18H36O2, structure formula: CH3(CH2)16COOH, molecular weight: 284.48.
SA is slightly soluble in cold water, ethanol and acetone, and is easily soluble in benzene, chloroform, diethyl ether, carbon tetrachloride, carbon disulfide, amyl acetate, toluene, etc. Wherein each gram of SA is dissolved in 2ml of trichloromethane, 5ml of benzene, 6ml of carbon tetrachloride and 21ml of ethanol.
Mouse, rat intravenous injection LC 50: (23 +/-0.7) mg/kg and (21.5 +/-1.8) mg/kg.
Stearic Acid (SA) and palmitic acid (PA, hexadecanoic acid, also known as palmitic acid) are typical representatives of Saturated Fatty Acids (SFAs) and have important physiological functions.
SA is widely found in nature, and almost all fats contain varying amounts of SA. The pure products of SA are white, soft and glossy small pieces, and exist in flue-cured tobacco leaves, burley tobacco leaves, aromatic tobacco leaves and smoke.
The animal fat content is higher, the beef tallow content can reach 24%, the vegetable oil content is lower, the tea oil content is 0.8%, the palm oil content is 6%, but the cocoa butter content is as high as 34%.
Researchers at the university of Deleston, Germany, have made one test of the "effect of chocolate on Parkinson's disease". 30 Parkinson patients (male and female halves, divided into two groups) were recruited, one group orally administered white chocolate (without cocoa powder) and the other group orally administered dark chocolate (with 85% cocoa powder). 50g/d, and the medicine is eaten in 2 times and is taken for 2 weeks continuously.
During the test: the dark chocolate group had reduced head and hand tremor, while the white chocolate group did not. The black chocolate is shown to have the function of relieving PD.
Before this time, researchers have made experiments using PD animal models, and the administration of cocoa powder to experimental animals has improved PD symptoms, indicating that cocoa powder is the key to preventing and treating PD.
German clinical medicine researchers believe that dark chocolate has a miraculous effect of improving PD symptoms because of the relationship with a large amount of cocoa powder contained in the dark chocolate, and the cocoa powder contains a natural phytochemical component phenylethylamine which can activate brain cells to generate more dopamine after entering a human body, so that the dark chocolate has the effect of improving PD symptoms. (Black chocolate capable of preventing Parkinson's disease 2015.10.08.)
The inventors do not believe this.
As mentioned previously, the content of Stearic Acid (SA) in cocoa butter is up to 34%, even 10% higher than in beef tallow.
A large number of studies have shown that Saturated Fatty Acids (SFA) can reduce the inflammatory response and antioxidant stress of the body by regulating lipid metabolism. Wherein SA antagonizes brain slice damage caused by oxidative stress through PI-3K and PPAR γ pathways. (WANGZJ, et a 1. neuropro protective effect of the fibrous acid induced stress phosphorus 1 accelerator 3-kinase path (J). Chem Biol Interact, 2006, 160 (1): 8O-87)
Studies have shown that it is important for the health of the body that SA and PA are in a reasonable ratio. (the effects of palmitic acid and stearic acids such as Helichong on the expression of HepG2 cell heme oxygenase-1 and nuclear transcription factor Nrf2 Acta Veterinaria etZootechnica Sinica 2016, 47 (3): 603-608)
It is reported in literature that healthy men are fed with high Stearic Acid (SA) every day, and after 4 weeks, compared with high Palmitic Acid (PA) diets, the incidence of thrombosis and arteriosclerosis is obviously reduced, the mean platelet volume, the activity of coagulation factor VII and the blood lipid concentration are reduced to a certain extent after SA ingestion, and the coagulation of platelets is obviously increased after PA ingestion. (FD Kelly, et al, auxiliary acid-rich diet improvees nutritional and nutritional ingredients in nutritional formulas [ J ]. EUR J CLIN NUTR volumes 55, pages 88-96 (2001))
The association of doctor Aliza P. Wingo , doctor Nichols T. Seyfried , professor Allani. Levey, and professor Thomas S. Wingo , all at the American college of medicine of Emmeri, aims to evidentially reveal the association between Cerebral Atherosclerosis (CA) and Alzheimer's disease. It is published on-line in Nature Neuroscience in Shared proteomic effects of cereral atherosclerosis and Alzheimer's disease on the human brasin No. 5/18 of 2020. (https:// doi.org/10.1038/s41593-020-
Recently, a study of 19 ten thousand people found: higher dairy intake is associated with lower prevalence of metabolic syndrome, diabetes and hypertension, and this association is more pronounced in whole milk products. (Balaji Bhavadhalini, et. (2020). Association of day con administration with methyl glycosides, hyperextension and diabetes in 147. 812 indeviduals from 21 counters. BMJ OpenDiab Res Care, DOI: 10.1136/bmjdr-2019-
This subverts the "common sense" that people have long thought skim milk to be healthier than whole milk.
Free Fatty Acids (FFA), also known as non-esterified fatty acids (NEFA), consist of oleic acid, palmitic acid, stearic acid, linoleic acid, and the like. The concentration of the blood is very low, and the normal value is 0.3-0.9 mmol/L. The concentration of FFA in serum is related to lipid metabolism, carbohydrate metabolism, endocrine function, etc.
Published in the Journal of Internal Medicine at 22.2.2002, a case-control study on the serum Free Fatty Acid (FFA) pattern and myocardial infarction risk from the medical institute of the norwegian oslo university, the oslo national health screening service and the central norwegian stfold hospital found: an increase in Stearic Acid (SA) content is associated with a reduction in risk.
Stearic Acid (SA) is significantly negatively correlated with intercellular adhesion molecule-1 (ICAM-1), while oleic acid is significantly positively correlated with ICAM-1. (JIM Serum free failure acid pattern and ask of myographical interaction: a case-control study)
ICAM-1, which is normally rarely expressed or only weakly expressed in tissue cells, can be expressed on the surface of various cells when stimulated by inflammatory factors and the like, thereby enhancing the adhesion between leukocytes or with extracellular matrix and promoting inflammatory reaction. (Melotti, P et al, Activation of NF-kB media ICAM-1 index into efficiency cells ex activated to an advanced vector gene other 20018 (18):1436-42 DOI: 10.1038/sj.gt.3301533)
Of course, there is not much research evidence for the health relationship of Saturated Fatty Acids (SFA) in the diet, and particularly Stearic Acid (SA) in the diet.
For example, an article published in Diabetes mellitus, the top journal Diabetes, on month 09, 2012, considers: high concentrations of stearic acid lead to insulin resistance. (Xia Chu et al, Sterol regulation Element-binding protein-1c media Inc of Postprandial stereoactive Acid, Potenial targeting for Improving the instrumentation Resistance, in Hyperlipidemia. doi: 10.2337/db 12-0139)
This is particularly true in relation to digestion and absorption of fat (fat), which has a low content of Free Fatty Acids (FFA) in serum, which requires sensitive methods for determination, and which is also related to factors such as interference of fatty acids produced by fat hydrolysis. There are of course analytical angle differences how the causal relationships between the variables under consideration are evaluated.
Lipids are divided into two major classes, fats (fat) and lipids (lipids). Normal people generally digest about 55 grams of lipids from food per person daily, with triglycerides accounting for over 90%, along with small amounts of phospholipids, cholesterol and its esters, and some Free Fatty Acids (FFA).
Since fat is insoluble in water and enzymatic reaction in vivo is carried out in aqueous solution, fat must be emulsified first for digestion, and bile salts from gallbladder play an important role in fat digestion.
One study in rats found that the mechanism of lowering cholesterol absorption by dietary Stearic Acid (SA) is that SA partially reduces cholesterol dissolution, while SA may regulate bile acid production. (Russell L Cowles, et al. digital Stearic Acid Alters Gallbaladder Bile Acid Composition in Hamsters FedCereal-Based Diets J Nutr. 2002 Oct;132(10): 3119-22.)
The absorption of long chain fatty acids is through the intestinal mucosa in the small intestine into the terminal lymphatic vessels of the intestinal mucosa, and the long chain fatty acids are re-lipidated with glycerol in the lymphatic vessels, and the re-synthesis of triglycerides occurs and then enter the blood. Furthermore, fatty acids need to be transported by apolipoprotein carrying after mobilization from adipocytes, but the Blood Brain Barrier (BBB) does not allow macromolecules to pass through.
The Blood Brain Barrier (BBB) is present between the Central Nervous System (CNS) and the blood and is an important physiological element for maintaining homeostasis in the brain. The barrier function is not only passive protection, but also can selectively pump out metabolic waste and harmful substances in the brain, including medicines. Only small molecule drugs with high lipid solubility and relative molecular mass less than 400 can pass through.
Many experts and scholars thought that "late 1970 s, numerous errors in dietary and nutritional recommendations by the various forms of official media channels in the european and american regions caused obesity flooding". (Chan Peng, Anhui province tumor hospital nutrition and metabolism treatment department nutrition suggestion error fatness flood micro signal number: tumor metabolism nutrition treatment 2019-03-06)
It is reported in the literature that "dietary stearic acid causes a reduction in visceral adipose tissue in Nude mice (Nude Mouse)". (Ming-CheShen, et al, digital stereogenic Acid Leads to a Reduction of Viscoel AdiposeTissue in atmospheric Nude Mice. PLoS ONE; Sep 2014, Vol. 9Issue 9, p 1.)
Visceral fat (Visceral Adipose) is not a newly discovered fat type. Visceral fat is one of the human fats, and unlike subcutaneous fat (tentatively "fat"), it surrounds human viscera and is found primarily in the abdominal cavity.
Most people accumulate a certain amount of visceral fat, which is beneficial to the protection of organs. However, truly harmful to our health is that when it becomes excessive, excess visceral fat is strongly associated with many diseases.
In addition to disturbing insulin, visceral adiposity inhibits secretion of adipocytokines such as leptin and the like. In addition, excessive visceral fat also releases proinflammatory cytokines, increases inflammatory response, and causes inflammation and disease deterioration. (Schwarz J. et al. Effects of kinetic front reduction light Fat, DeNovo Lipogenesis, and in vivo Kinetics in Childen With ease. gateway science 2017 Sep;153(3):743-
Fatty Acid Synthase (FASN; also abbreviated as FAS), also known as Fatty Acid Synthase, is localized in the cytosol and is a multi-enzyme complex with multiple functions that catalyze the synthesis of C in De novo biosynthesis16Palmitic acid (or C)18Stearic acid (b). Normally, FASN is mainly expressed in tissues such as brain, lung, liver, fat, and mammary gland during lactation.
Currently, it is widely believed to play an important role in energy metabolism, associated with the occurrence and development of many diseases such as cancer, multiple sclerosis, cardiovascular disease, obesity, fatty liver, nerve cell injury, different forms of inflammation, and blood-borne tumors.
Cell Stem Cell publication long term at 5/7/2020 first reported a functional association between fatty acid synthase-mediated lipid metabolism disorders and brain cognitive function. (Megan Bowers, Tong Liang, DanielGonzalez-Bohorquez, et al, FASN-Dependent Lipid Metabolism Links neuron Activity to Learning and Memory defaults, Cell Stem Cell (2020) doi:10.1016/j. Stem. 2020.04.002)
Researchers state that future therapies for the treatment of cognitive dysfunction and a variety of diseases associated with neuronal cell death are expected, including Parkinson's Disease (PD) and Alzheimer's Disease (AD).
Nanoparticles have many specific physicochemical properties and elicit some specific biological effects. The so-called nano effect. The concept of nanomaterials has only emerged for decades, but the history of human use of nanomaterials dates back two thousand years.
The reason why the ash of the candle collected in ancient China as the raw material of the ink does not fade the calligraphy and painting made by the candle for thousands of years is that the ash used is actually nano-scale carbon black.
The nano-scale medicine can enter capillary vessels, freely flow in a blood circulation system, and can also pass through cells, and be absorbed by tissues and cells in a pinocytosis way, so that the bioavailability is improved; can eliminate the limitation of special biological barriers on the action of drugs, such as blood brain barrier, blood eye barrier, cell biological membrane barrier, etc.
Nanoparticles are generally defined in the field of drug delivery systems as having a size of 1-1000nm, and it is clear that this range includes submicron particles having a size above 100 nm. According to the nano-size range defined in the pharmaceutical field and the molecular state of the drug in the nano-carrier, the fundamental properties of the drug are not changed, and the essence of many nano-products and the scientific connotation of nano-technology are not nearly different.
The preparation method of the nanomaterial is classified into a solid method, a liquid method, and a gas method according to the state of the raw materials for preparation. Currently, more classification methods are used. Generally divided into chemical methods, hydrothermal method, hydrolysis method, melting method, etc.; physical methods, such as vapor condensation, explosion, electric spark, ion sputtering, mechanical grinding, and low-temperature plasma; there are also synthetic methods: such as plasma enhanced chemical deposition (PECVD), laser induced chemical deposition (LICVD), etc.
Returning to the previous, the question of why smoking has the potential to protect against PD, AD and obesity.
Patent "inhibitor of visceral fat reduction in Parkinson's disease patient" by Olympic group of Olympic Riemers, Japan (grant publication No. CN 102665710B) the inventors of this patent describe in the patent specification:
the present inventors have focused on visceral fat, which is one of body fat elements, and as a result of intensive studies, have found that an oil or fat effective for reduction of visceral fat in healthy humans can suppress reduction of visceral fat content in rats in models of parkinson's disease, thereby completing the present invention.
The visceral fat reduction inhibitor is C8Or C10Saturated Fatty Acid (SFA) is a fat of structural fatty acid. Such as caprylic capric glyceride, a medium carbon chain ester product, also known as MCT (or ODO).
The inventor always insists on researching and exploring possible protection mechanisms of smoking on PD, AD and obesity from Saturated Fatty Acid (SFA) which is contained in cigarette smoke and generally considered as 'bad fatty acid', and analyzes layer by layer according to two Chinese and western philosophies with the wonderness of different cooperations, namely 'phenomenon, namely essence' and 'existence, namely reasonable'.
The inventor finds that the stearic acid in a nano state can resist obesity mice to gain weight, improve the memory and cognition of AD mice and improve the health state of PD mice when being administered to experimental mice.
Although the mechanism of action of the treatment regimen with nano-stearic acid does not address the source of the disease, like insulin does not treat diabetes, analgesics do not address the source of pain. But takes effect quickly, which is beneficial to quickly stopping the malignant development process of the disease.
The application of the nano stearic acid as an active ingredient in the preparation of products has no relevant documents and patents.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: overcomes the defects of the prior art, provides the application of nano stearic acid as an active ingredient in preparing medicaments, foods, food additives or feed additives and a preparation method thereof, and is used for improving the health of mammals.
The technical scheme adopted by the invention for solving the technical problems is as follows:
use of nano stearic acid as an active ingredient for the preparation of a medicament, a food additive or a feed additive.
The nano stearic acid has the nano particle size of 1-1000nm, preferably less than 600nm, and more preferably less than 100 nm.
Further, the medicament is used for treating and/or preventing a disease associated with lipid metabolism, wherein the disease is obesity, Alzheimer disease or Parkinson disease.
Such diseases include, but are not limited to, obesity, Alzheimer's Disease (AD), and Parkinson's Disease (PD).
Nonalcoholic fatty liver disease (NAFLD) has formally been renamed to metabolic-related fatty liver disease (MAFLD). High levels of ICAM-1 are detectable in hepatocytes of non-alcoholic fatty liver disease (NAFLD) patients, while the higher the level of ICAM-1, the higher the risk of atherosclerosis in non-alcoholic fatty liver disease patients.
As previously described, free stearic acid in blood is negatively associated with ICAM-1.
It is further contemplated that the nanostearic acids can be used to produce products resistant to fatty liver disease, including metabolic-related fatty liver disease (MAFLD).
Furthermore, the dosage form of the medicine is granules, capsules, microcapsules, soft capsules, gel, oral liquid, tablets, powder, suppositories, injection, sublingual tablets, ear drops, nose drops or spray, and the dosage forms are all physiologically acceptable preparations.
Further, the formulations may be administered in dosage units containing a predetermined amount of the active ingredient per dosage unit. Such units may be determined according to the condition to be treated, the method of administration and the age, weight and condition of the subject in need thereof. The nanostearic acid, or formulation thereof, can be administered in dosage units containing a predetermined amount of active ingredient per dosage unit. In terms of the amount of nano stearic acid as an active ingredient administered daily, it is preferable that the amount is not less than 10 mg/day and not less than 1 time/day for human patients.
The formulation may be adapted for administration by any desired suitable method, including by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. And such formulations are prepared, for example, by bringing into association the active ingredient with excipients or auxiliaries, using all methods known in the art.
Formulations suitable for oral administration may be presented as discrete units, for example capsules or tablets; powder or granules; a solution or suspension; edible foams or foam foods; or an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
Also in the case of oral administration in the form of tablets or capsules, the active ingredient may be mixed with oral, non-toxic and inert excipients, including edible carbohydrates, starch or mannitol. Perfumes, preservatives, dispersants and dyes may also be present.
It can be used for filling and forming gelatin shell, and making into capsule. Glidants and lubricants, for example highly disperse silicic acid in solid form, talc, magnesium stearate, calcium stearate or polyethylene glycol, can be added to the powder mixture before the filling operation.
Oral liquids, such as solutions, syrups and elixirs, include those prepared in dosage unit form so that a given quantity contains a predetermined amount of the nano stearic acid. Solubilizers and emulsifiers, preservatives, flavor additives, such as peppermint oil, or natural sweeteners or saccharin, or other artificial sweeteners, and the like, may also be added.
Another object of the present invention is to provide a method for preparing nano stearic acid, comprising the following steps:
1) preparing a surfactant into an aqueous solution;
2) placing the reaction container in a constant-temperature water bath at 65-90 ℃, and adding the aqueous solution prepared in the step 1) into the reaction container;
3) dissolving stearic acid in an organic solvent, and then injecting into the reaction vessel at a constant speed;
4) continuously stirring, adding cooling water when the solution in the reaction container is milky, and then placing the reaction container on ice to continuously stir for 0.5-3.0 h at the rotating speed of 0.7-1.3 k rpm;
5) and after stirring, transferring the reactants in the reaction container to a centrifuge tube, washing with water, and freeze-drying to obtain the nano stearic acid.
The present inventors have initiated this study based on non-volatile saturated fatty acids in cigarette smoke, of which fatty acids are only one, C18-0. The present invention does not exclude but comprises other saturated fatty acids and mixtures of saturated fatty acids thereof, such as C8 and/or C10 saturated fatty acids and mixtures thereof.
Further, the surfactant is MYRJ59, MYRJ53 or tween 80, and the organic solvent is one or more of chloroform or a solution of chloroform and acetone or chloroform and methanol mixed in a volume ratio of 2: 1.
Further, the stearic acid is animal-derived stearic acid, plant-derived stearic acid or a mixture of two kinds of stearic acid.
Preferably, the stearic acid is plant-derived stearic acid, and the trichloromethane contains 0.6-0.9% of ethanol as a stabilizer.
Further, the dosage ratio of the surfactant to the distilled water in the step 1) is as follows: every 100mg to 350mg of the surfactant is dissolved in 30mL of water.
Further, the adding amount of the cooling water in the step 4) is 7-13 mL.
The invention relates to nano stearic acid and a preparation method and application thereof, and has the following beneficial effects: the nano stearic acid is used as an active ingredient to be applied to preparation of medicines, foods, food additives or feed additives, improves the health of mammals, can resist the increase of body weight of a human body, reduces obesity, can improve the memory and cognition of AD patients, improves the health state of PD patients, provides a new method, a new way and a new medicine for treating obesity, Alzheimer Disease (AD) or Parkinson disease, and expands the application of the nano stearic acid.
Drawings
FIG. 1 shows the electron microscope (X60000) of the preparation method A of nano stearic acid.
Detailed Description
The invention is further illustrated with reference to the following figures and examples, which are not intended to limit the scope of the invention in any way.